Showing results (81-90 of 123) with videos related to
Sort By:
Pageof 13
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignanciesJ P Braybrooke, E Boven, N P Bates, et al.Journal of Pharmaceutical and Biomedical Analysis|December 1, 1995
High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasmaR van Gijn, E Havik, E Boven, et al.Blood|June 25, 1998
Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapyH J Haisma, M F Sernee, E Hooijberg, et al.British Journal of Cancer|April 21, 2005
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration scheduleE Boven, M Westerman, C J van Groeningen, et al.British Journal of Cancer|February 11, 2010
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibA A M van der Veldt, M R Meijerink, A J M van den Eertwegh, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2005
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancerA H G Hansma, H J Broxterman, I van der Horst, et al.British Journal of Cancer|February 24, 2001
A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancerP H Houba, E Boven, I H van der Meulen-Muileman, et al.The British Journal of Cancer. Supplement|July 1, 1990
Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and manH J Haisma, M A Kessel, C Silva, et al.European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenograftsE Boven, M Verschraagen, T M Hulscher, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2010
Phase I trial of SU14813 in patients with advanced solid malignanciesW Fiedler, G Giaccone, P Lasch, et al.Pageof 13